Pancreatic cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 67
• PD-1 39
• TP53 4
• mTOR 0
• PI3K 0
• STAT3 0
• PD-L1 20
• CLDN18 21
• EGFR 11
• RAS 17
• BRCA2 8
• AKT 0
• BRCA1 10
• ERK 0
• MAPK 1
• PARP 9
• STING 0
• HER2 13
• MYC 0
• YAP 0
• MEK 5
• PALB2 9
• CTLA-4 9
• VEGF 3
• AMPK 0
• ATM 3
• CD40 2
• CXCR4 0
• HIF-1 0
• JNK 0
• NRF2 0
• CDKN2A 3
• GLP-1 2
• NRAS 5
• PRMT5 6
• IL-6 0
• PPAR 0
• PTEN 0
• BCL-2 0
• FAK 1
• IL-15 1
• JAK 0
• TROP2 3
• BRAF 2
• MET 2
• B7-H3 2
• CDK4/6 0
• CTNNB1 0
• FGFR 1
• HSP90 0
• HDAC 0
• KEAP1 1
• CD47 0
• METTL3 0
• MUC1 3
• AXL 1
• CCR5 0
• HER3 1
• HMGB1 1
• NTRK 1

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Assessing autophagic dependencies in the context of RAS inhibition in pancreatic ductal adenocarcinoma

  Univ of North Carolina Chapel Hill· Chapel Hill, United States· US$37,011 awarded in fiscal year 2026· until Sept 2029

• FDA · R01

  Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients

  Marker Therapeutics, Inc.· Houston, United States· US$645,493 awarded in fiscal year 2026· until Aug 2030

• NIH NIAMS · R21

  Nuclear Receptors In Cancer Cachexia

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$200,604 awarded in fiscal year 2026· until Jul 2028

• NIH NCI · U01

  The role of circadian gene regulation in pancreatic cancer progression and immune evasion

  University of Rochester· Rochester, United States· US$626,555 awarded in fiscal year 2026· until Aug 2031

• NIH NIAMS · R56

  Mitochondrial permeability transition in cancer cachexia

  University of Florida· Gainesville, United States· US$307,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Immunity under Pressure: Mapping Compression Driven Tumor–Immune Rewiring to Potentiate Immunotherapy in Pancreatic Cancer (MechanoImmunoMap)

  University of Cyprus· Nicosia, Cyprus· EU contribution €1,500,000· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glycoengineering for Immune Modulation in Precision Anti-Cancer Therapies (GlycoIMPACT)

  Universitat Wien· Wien, Austria· EU contribution €230,185· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-Generation Radiopharmaceuticals for Glioblastoma and Pancreatic Cancer: A 3D Perspective (radio3D)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spain· EU contribution €4,366,500· until Dec 2030· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Evoking anti-tumor immunity in pancreatic cancer (Evoke-PDAC)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €2,497,125· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

10 of 864 running projects, newest first. Listed amounts together: US$468.4m + €177.8m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

  NCT06130254· M.D. Anderson Cancer Center· Updated 9 Apr 2026

  “Sponsor discontinued the trial”Registry text, quoted unchanged. Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Updated 6 Nov 2025

  “The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

  NCT06065059· Tango Therapeutics, Inc.· Updated 13 Aug 2024

  “Terminated due to safety”Registry text, quoted unchanged. Source

• Terminated

  In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

  NCT03492164· Abramson Cancer Center at Penn Medicine· Updated 12 Jun 2024

  “Early analysis of images after 6 patients showed no activity of the radiotracer in this patient population.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

  NCT04550494· National Cancer Institute (NCI)· Source

• APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

  NCT04858334· National Cancer Institute (NCI)· Source

• Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy

  NCT03404960· University of Pennsylvania· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 47
• Mendelian Randomization Analysis 29
• CRISPR-Cas Systems 16
• Gene Expression Profiling 123
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 10
• Proteomics 55
• Metabolomics 34
• Mass Spectrometry 10
• Flow Cytometry 32
• Immunohistochemistry 70
• Liquid Biopsy 30
• Circulating Tumor DNA 29
• Xenograft Model Antitumor Assays 302
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 117
• Machine Learning 58
• Deep Learning 55
• Cohort Studies 108
• Genome-Wide Association Study 24

• CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer.

  Cancer Lett, Sept 2026

• Double-end blocker and split input mediated CRISPR-Cas12a system for modular single-base mutation detection with low abundance.

  Biosens Bioelectron, Aug 2026

• BASELINE: a CRISPR base editing platform for mammalian-scale single-cell lineage tracing.

  Nucleic Acids Res, Jul 2026

• Genotypic and Phenotypic Diversity as a Function of CRISPR-Directed Gene Knock-Out of NRF2 in Pancreatic Adenocarcinoma Cells, a Feasibility Study.

  Biomolecules, Jun 2026

• STAR-CRISPR: a one-pot ultraspecific CRISPR strategy for rapid, visualized SNV detection and genotyping in point-of-care diagnostics.

  Talanta, May 2026

• Chromosomal instability induced by CRISPR/Cas9: implications for pancreatic cancer therapy.

  J Clin Invest, May 2026

• Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer.

  J Clin Invest, May 2026

• An autochthonous CRISPR activation screening platform for characterizing tissue-specific oncogene selection.

  Cell Rep Med, Apr 2026

• CbAgo-enriched Cas12a biosensor for cancer mutations screening.

  Anal Chim Acta, Mar 2026

• Pancreatic-targeted lipid nanoparticles based on organ capsule filtration.

  Nature, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.